Experiences of Daughters Caring for a Parent With Alzheimer's Disease Living at Home

2021 ◽  
pp. 1-9
Author(s):  
Christine DiLeone
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
At Home

P2-399: RAMCIP PROJECT, A ROBOTIC ASSISTANT TO SUPPORT ALZHEIMER'S DISEASE PATIENTS AT HOME: A NOVEL APPROACH IN CAREGIVING

2016 ◽  
Vol 12 ◽  
pp. P798-P798
Author(s):  
Carla Abdelnour ◽  
Natalia Tantinya ◽  
Joan Hernandez ◽  
Elvira Martin ◽  
Silvia Garcia ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Novel Approach ◽  
Robotic Assistant ◽  
At Home

Timing of sleep and wakefulness in Alzheimer's disease patients residing at home

1992 ◽  
Vol 31 (11) ◽  
pp. 1163-1165 ◽  
Author(s):  
Donald L. Bliwise ◽  
Jared R. Tinklenberg ◽  
Jerome A. Yesavage
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
At Home

scholarly journals Monthly At-Home Computerized Cognitive Testing to Detect Diminished Practice Effects in Preclinical Alzheimer's Disease

2022 ◽  
Vol 13 ◽  
Author(s):  
Roos J. Jutten ◽  
Dorene M. Rentz ◽  
Jessie F. Fu ◽  
Danielle V. Mayblyum ◽  
Rebecca E. Amariglio ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Decline ◽  
Pet Imaging ◽  
Cognitive Testing ◽  
Practice Effects ◽  
Aging Brain ◽  
Amyloid Burden ◽  
Preclinical Ad ◽  
At Home

Introduction: We investigated whether monthly assessments of a computerized cognitive composite (C3) could aid in the detection of differences in practice effects (PE) in clinically unimpaired (CU) older adults, and whether diminished PE were associated with Alzheimer's disease (AD) biomarkers and annual cognitive decline.Materials and Methods:N = 114 CU participants (age 77.6 ± 5.0, 61% female, MMSE 29 ± 1.2) from the Harvard Aging Brain Study completed the self-administered C3 monthly, at-home, on an iPad for one year. At baseline, participants underwent in-clinic Preclinical Alzheimer's Cognitive Composite-5 (PACC5) testing, and a subsample (n = 72, age = 77.8 ± 4.9, 59% female, MMSE 29 ± 1.3) had 1-year follow-up in-clinic PACC5 testing available. Participants had undergone PIB-PET imaging (0.99 ± 1.6 years before at-home baseline) and Flortaucipir PET imaging (n = 105, 0.62 ± 1.1 years before at-home baseline). Linear mixed models were used to investigate change over months on the C3 adjusting for age, sex, and years of education, and to extract individual covariate-adjusted slopes over the first 3 months. We investigated the association of 3-month C3 slopes with global amyloid burden and tau deposition in eight predefined regions of interest, and conducted Receiver Operating Characteristic analyses to examine how accurately 3-month C3 slopes could identify individuals that showed >0.10 SD annual decline on the PACC-5.Results: Overall, individuals improved on all C3 measures over 12 months (β = 0.23, 95% CI [0.21–0.25], p < 0.001), but improvement over the first 3 months was greatest (β = 0.68, 95% CI [0.59–0.77], p < 0.001), suggesting stronger PE over initial repeated exposures. However, lower PE over 3 months were associated with more global amyloid burden (r = −0.20, 95% CI [−0.38 – −0.01], p = 0.049) and tau deposition in the entorhinal cortex (r = −0.38, 95% CI [−0.54 – −0.19], p < 0.001) and inferior-temporal lobe (r = −0.23, 95% CI [−0.41 – −0.02], p = 0.03). 3-month C3 slopes exhibited good discriminative ability to identify PACC-5 decliners (AUC 0.91, 95% CI [0.84–0.98]), which was better than baseline C3 (p < 0.001) and baseline PACC-5 scores (p = 0.02).Conclusion: While PE are commonly observed among CU adults, diminished PE over monthly cognitive testing are associated with greater AD biomarker burden and cognitive decline. Our findings imply that unsupervised computerized testing using monthly retest paradigms can provide rapid detection of diminished PE indicative of future cognitive decline in preclinical AD.

scholarly journals Can smart homes extend people with Alzheimer’s disease stay at home?

2017 ◽  
Vol 11 (1) ◽  
pp. 6-12 ◽  
Author(s):  
Alberto Brunete González ◽  
Micheline Selmes ◽  
Jacques Selmes
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Leisure Activities ◽  
Smart Homes ◽  
Information And Communications Technology ◽  
Smart Devices ◽  
Home Automation ◽  
Content Type ◽  
Technical Solutions ◽  
At Home

Purpose The purpose of this paper is to analyse the needs of people with Alzheimer’s disease and their caregivers in terms of information and communications technology (ICT) and home automation, and how to foster the use of smart devices in their homes and also, to determine whether the use of ICT can extend people with Alzheimer’s disease stay at home in the first stages of the illness, while facilitating their caregivers’ tasks. Design/methodology/approach Groups of caregivers, ICT researchers and Alzheimer’s disease experts were gathered to discuss the utility of several solutions. Sessions were grouped into four topics: safety, leisure, activities of daily living and friendly atmosphere. In total, 23 ICT-based solutions to improve life at home of people with Alzheimer’s disease were analysed and grouped under “no interest”, “some interest” and “very interesting”. Caregivers rated these solutions and suggested improvements to them. Findings In total, 18 out of 23 proposals were considered “very interesting”, meaning that caregivers considered that they could truly improve the lives of people with Alzheimer’s disease. Caregivers also suggested how to progressively introduce these technical solutions into their homes. Originality/value ICT and home automation advances could be very useful if used conveniently. Caregivers consider that smart homes can help people with Alzheimer’s disease in the security, leisure and daily tasks fields, increasing the time they can live alone in their own homes.

scholarly journals Pilot Evaluation of the Unsupervised, At-Home Cogstate Brief Battery in ADNI-2

2021 ◽  
pp. 1-11
Author(s):  
Chris J. Edgar ◽  
Eric Siemers ◽  
Paul Maruff ◽  
Ronald C. Petersen ◽  
Paul S. Aisen ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Bring Your Own Device ◽  
Cohen’S D ◽  
Small Effect Size ◽  
Cohen's D ◽  
Over Time ◽  
At Home

Background: There is a need for feasible, scalable assessments to detect cognitive impairment and decline. The Cogstate Brief Battery (CBB) is validated for Alzheimer’s disease (AD) and in unsupervised and bring your own device contexts. The CBB has shown usability for self-completion in the home but has not been employed in this way in a multisite clinical trial in AD. Objective: The objective of the pilot was to evaluate feasibility of at-home, self-completion of the CBB in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) over 24 months. Methods: The CBB was included as a pilot for cognitively normal (CN) and mild cognitive impairment (MCI) participants in ADNI-2, invited to take the assessment in-clinic, then at at-home over a period of 24 months follow-up. Data were analyzed to explore acceptability/usability, concordance of in-clinic and at-home assessment, and validity. Results: Data were collected for 104 participants (46 CN, 51 MCI, and 7 AD) who consented to provide CBB data. Subsequent analyses were performed for the CN and MCI groups only. Test completion rates were 100%for both the first in-clinic supervised and first at-home unsupervised assessments, with few repeat performances required. However, availability follow-up data declined sharply over time. Good concordance was seen between in-clinic and at-home assessments, with non-significant and small effect size differences (Cohen’s d between -0.04 and 0.28) and generally moderate correlations (r = 0.42 to 0.73). Known groups validity was also supported (11/16 comparisons with Cohen’s d≥0.3). Conclusion: These data demonstrate the feasibility of use for the CBB for unsupervised at-home, testing, including MCI groups. Optimal approaches to the application of assessments to support compliance over time remain to be determined.

scholarly journals Diagnose it yourself: will there be a home test kit for Alzheimer’s disease?

2021 ◽  
Vol 11 (2) ◽  
pp. 167-176
Author(s):  
Felix Menne ◽  
Carola G Schipke
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Preventive Measures ◽  
Neurodegenerative Process ◽  
Home Test ◽  
Test Strategies ◽  
Test Kit ◽  
Low Threshold ◽  
Novel Approaches ◽  
At Home

Alzheimer’s disease is the most common neurodegenerative process leading to dementia. To date, there is no curative approach; thus, establishing a diagnosis as early as possible is necessary to implement preventive measures. However, today’s gold standard for diagnosing Alzheimer’s disease is high in both cost and effort and is not readily available. This defines the need for low-effort and economic alternatives that give patients low-threshold access to testing systems at their general practitioners or even at home for an independent retrieval of a biologic specimen. This perspective gives an overview of established and novel approaches in the field and speculates on the future of test strategies eventually technically implementable at home.

Sign in / Sign up

Export Citation Format

Share Document